EAST WINDSOR TOWNSHIP, NJ—Aurobindo Pharma USA has acquired a 90-acre tract on Windsor Center Drive here and plans to develop the site as a major pharmaceutical manufacturing and distribution center.

The generic pharmaceutical and manufacturing company's expansion was announced on Tuesday by Township Mayor Janice S. Mironov who stated that the Dover, NJ-based firm had acquired a parcel near the 43,000-square-foot Patscentre building, now occupied by Novo Tech, a new Township pharmaceutical R&D company. The new facility is expected to generate at least 300 new jobs at the East Windsor location when fully operational.

No financial information on the land purchase or the scope of the warehouse-distribution facility was released. Headquartered in Hyderabad, India, Aurobindo's main US manufacturing center is located in Dayton, NJ. The East Windsor location will be the company's main distribution center and also will provide another site for manufacturing.

Mayor Mironov says of the firm's expansion, “We are excited that Aurobindo has chosen East Windsor for their new warehouse and distribution center, bringing new tax dollars and new jobs to our community. This expansion here by Aurobindo, a global corporation, represents the attraction to East Windsor of another high-tech, high growth-potential company in our Einstein's Alley corridor. East Windsor is a great location for this type of company, and we are pleased to add Aurobindo to the many pharmaceutical related firms which have chosen to locate in East Windsor, including Novotec Pharma, Hovione, Elementis, CoreTech Solutions, Aprecia, Aurex Laboratories, Sabinsa, and Windsor Labs.”

In a statement, Aurobindo USA's CEO Robert Cunard states, “We at Aurobindo Pharma are very excited about our recent acquisition and planned expansion into East Windsor. We have appreciated the valuable assistance and guidance of the mayor and her team, who have been great partners and extremely helpful to our company in moving forward with our acquisition and planned expansion.”